122 related articles for article (PubMed ID: 34170505)
1. Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database.
Weil-Olivier C; Taha MK; Emery C; Bouée S; Beck E; Aris E; Loncle-Provot V; Nachbaur G; Pribil C
Infect Dis Ther; 2021 Sep; 10(3):1607-1623. PubMed ID: 34170505
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM).
Shen J; Bouée S; Aris E; Emery C; Beck EC
Infect Dis Ther; 2022 Feb; 11(1):249-262. PubMed ID: 34791633
[TBL] [Abstract][Full Text] [Related]
3. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.
Weil-Olivier C; Taha MK; Bouée S; Emery C; Loncle-Provot V; Nachbaur G; Beck E; Pribil C
Hum Vaccin Immunother; 2022 Dec; 18(1):2021764. PubMed ID: 35192785
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.
Huang L; Heuer OD; Janßen S; Häckl D; Schmedt N
PLoS One; 2020; 15(1):e0228020. PubMed ID: 31990941
[TBL] [Abstract][Full Text] [Related]
5. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans.
Bénard S; Wright C; Voisine J; Olivier CW; Gaudelus J
J Infect Public Health; 2016; 9(3):339-47. PubMed ID: 26688376
[TBL] [Abstract][Full Text] [Related]
6. A database study of clinical and economic burden of invasive meningococcal disease in France.
Huang L; Fievez S; Goguillot M; Marié L; Bénard S; Elkaïm A; Tin Tin Htar M
PLoS One; 2022; 17(4):e0267786. PubMed ID: 35486581
[TBL] [Abstract][Full Text] [Related]
7. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ
Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286
[TBL] [Abstract][Full Text] [Related]
8. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico.
Chacon-Cruz E; Lopatynsky-Reyes EZ; Huerta-Garcia G; Cervantes-Apolinar MY; Guzman-Holst A; Van Oorschot D
Hum Vaccin Immunother; 2022 Nov; 18(6):2103319. PubMed ID: 35921223
[TBL] [Abstract][Full Text] [Related]
10. Costs and mortality associated with HIV: a machine learning analysis of the French national health insurance database.
Prodel M; Finkielsztejn L; Roustand L; Nachbaur G; De Leotoing L; Genreau M; Bonnet F; Ghosn J
J Public Health Res; 2021 Nov; 11(2):. PubMed ID: 34850620
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.
Taha MK; Weil-Olivier C; Bouée S; Emery C; Nachbaur G; Pribil C; Loncle-Provot V
Hum Vaccin Immunother; 2021 Jun; 17(6):1858-1866. PubMed ID: 33449835
[TBL] [Abstract][Full Text] [Related]
12. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.
Wang B; Haji Ali Afzali H; Marshall H
Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada.
Rampakakis E; Vaillancourt J; Mursleen S; Sampalis JS
Pediatr Infect Dis J; 2019 Mar; 38(3):253-257. PubMed ID: 30763284
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
15. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
[TBL] [Abstract][Full Text] [Related]
16. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
[No Abstract] [Full Text] [Related]
17. Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data.
Fagnani F; Laurendeau C; de Zelicourt M; Marshall J
Epilepsia Open; 2022 Dec; 7(4):633-644. PubMed ID: 36029029
[TBL] [Abstract][Full Text] [Related]
18. Lifetime costs of invasive meningococcal disease: A Markov model approach.
Wang B; Haji Ali Afzali H; Giles L; Marshall H
Vaccine; 2019 Oct; 37(46):6885-6893. PubMed ID: 31594708
[TBL] [Abstract][Full Text] [Related]
19. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of invasive meningococcal disease and its sequelae: a population-based study in Italian primary care, 2000-2019.
Lapi F; Marconi E; Vetrano DL; Rossi A; Lagolio E; Baldo V; Cricelli C
Fam Pract; 2023 Jun; ():. PubMed ID: 37262015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
